Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome – Nasdaq

Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome  Nasdaq

MENLO PARK, Calif., Dec. 13, 2018– Corcept Therapeutics Incorporated announced today that the United States Patent and Trademark Office has given.